Tectonic Therapeutic Inc. (TECX)
16.80
-1.09 (-6.09%)
At close: Apr 03, 2025, 2:27 PM
Company Description
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Tectonic Therapeutic Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Dr. Alise S. Reicin M.D., Ph.D. |
Contact Details
Address: 490 Arsenal Way Watertown, Massachusetts United States | |
| Website | https://tectonictx.com |
Stock Details
| Ticker Symbol | TECX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 878972108 |
| ISIN Number | US8789721086 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, Chief Executive Officer, Secretary & Director |
| Daniel Lochner M.B.A. | Chief Financial Officer |
| Anthony Muslin M.D. | Chief Development Officer |
| Barry Rubenstein M.S. | Senior Vice President of People & Culture |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer |
| Dr. Timothy A. Springer M.B.A., Ph.D. | Independent Director |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences |